Leronlimab
(Redirected from PRO 140)
Monoclonal antibody used in the treatment of HIV and cancer
Leronlimab (also known as PRO 140) is a humanized monoclonal antibody that targets the CCR5 receptor. It is primarily being investigated for its potential use in the treatment of HIV/AIDS and certain types of cancer.
Mechanism of Action
Leronlimab works by binding to the CCR5 receptor, which is a protein on the surface of certain immune cells. The CCR5 receptor is used by the HIV virus to enter and infect host cells. By blocking this receptor, Leronlimab prevents the virus from entering these cells, thereby inhibiting its replication and spread.
In addition to its role in HIV treatment, the CCR5 receptor is also involved in the migration of cancer cells and the immune response to tumors. This has led to research into the use of Leronlimab as a potential treatment for metastatic cancer.
Clinical Trials
Leronlimab has undergone several clinical trials to evaluate its safety and efficacy. In HIV treatment, it has been tested as a monotherapy and in combination with other antiretroviral drugs. Results have shown that Leronlimab can significantly reduce viral load in patients with multi-drug resistant HIV.
In cancer research, Leronlimab is being studied for its ability to inhibit metastasis and improve the immune system's response to tumors. Early-phase trials have shown promising results, particularly in patients with triple-negative breast cancer.
Side Effects
The most common side effects of Leronlimab include injection site reactions, such as redness and swelling. Other potential side effects may include headache, fatigue, and nausea. As with any investigational drug, the full spectrum of side effects is still being studied.
Regulatory Status
As of 2023, Leronlimab is not yet approved by the FDA or other major regulatory bodies. It is currently available through clinical trials and expanded access programs for patients who meet specific criteria.
Also see
| Monoclonal antibodies | ||||||||
|---|---|---|---|---|---|---|---|---|
This Monoclonal antibodies related article is a stub.
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
